Shares of Admedus Ltd (ASX: AHZ) received a welcome boost this morning after the company announced that it had been granted a Medical Device Licence to sell its flagship CardioCel product in Canada. The shares rose 3.9% to be trading at 13.5 cents, compared to a 1% gain for the benchmark ALL ORDINARIES (INDEXASX: XAO) index.
So What: CardioCel is a regenerative tissue product which is gaining popularity amongst surgeons as a way to repair congenital holes and other damage inside the human heart. Gaining a licence for the Canadian market is another important stepping stone for the company which has already received 510k clearance in the U.S. and CE Mark approval in Europe. In Australia, it is also under the early access Authorised Prescriber Scheme.
Following today’s announcement, Admedus’ CEO Lee Rodne said: “The Canadian approval is another important step in the global launch of CardioCel and will add revenue growth for the Admedus Group.”
Now What: Following on from an incredible run in 2013 (which saw its shares rally approximately 675%), Admedus’ shares have actually fallen by 12.9% since the beginning of the year. As an investor who bought into the stock late in the game, I still like what the future could hold for Admedus and am certainly excited by its global expansion strategy.
Before committing to Admedus however, investors ought to remember that this is a high-risk/high-reward play. As such, it would be wise to limit your investment to a small amount of capital while focusing the majority of your cash on established companies with proven potential. As a perfect example, The Motley Fool’s top investment advisor, Scott Philips, has just announced his BEST stock to buy in 2015, and I couldn’t agree more with what he’s come up with.
Hot off the presses! The Motley Fool’s top stock for 2015 is a sexy ASX tech company with a stunning track record and plenty of room to run. Discover our analysts’ hands-down favourite bet for 2015 in this brand-new FREE report. Simply click here to grab your copy.
Motley Fool contributor Ryan Newman owns shares in Admedus Ltd.